{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T09:50:16Z","timestamp":1777024216328,"version":"3.51.4"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Behavioral and psychological symptoms of dementia (BPSD) have a high prevalence, and their presence is associated with a severe impact in terms of social costs. However, dedicated clinical tools or biomarkers to detect these symptoms are lacking. Thus, BPSD management in clinical settings is challenging. The aim of this study was to investigate the perception and the treatment strategies for BPSD in Italian centers working in the dementia field.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multicenter, national survey was developed by BPSD Study Group of the Italian Neurological Society for Dementia (SINDEM). The survey consisted of a semi-structured questionnaire that was e-mailed to SINDEM members, dementia centers part of the national network of memory clinics (Centers for Cognitive Deterioration and Dementia [CDCD]), and clinicians working in dementia care settings. The questions were focused on (1) perceived global frequency and relevance of BPSD; (2) tools used to assess BPSD; (3) pharmacological treatment for psychosis, apathy, agitation, aggression, depression, anxiety, sleep, and nutrition disturbances; (4) non-pharmacological treatments; (5) drugs side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One-hundred and thirty-six clinicians participated in this study. Seventy-nine participants worked in a CDCD and 57 in other settings. The perceived frequency of BPSD was 74%. BPSD are detected by means of a clinical assessment for 96.3% or a caregiver interview for 97%. For psychosis treatment the first choice was atypical antipsychotics (83.3%), followed by typical antipsychotic (8.9%) and antidepressants (4.8%). For agitation, atypical antipsychotics were the first-choice treatment in 64% of cases and antidepressants in 16.1%. For aggression, the most used drugs were atypical antipsychotics (82.9%). For anxiety, 55.2% use antidepressants, 17.9% use atypical antipsychotics, and 16.9% use benzodiazepines. Interestingly, most of the centers apply non-pharmacological treatments for BPSD. Some differences emerged comparing the responses from CDCD and other care settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The survey results revealed many differences in BPSD perception, treatment options, and observed side effect according to the clinical setting. This variability can be explained by the absence of clear guidelines, by differences in patients' characteristics, and by clinical practice based on subjective experience. These results suggest that producing guidelines for the pharmacological treatment of BPSD is a major need.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2022.843088","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T16:26:05Z","timestamp":1681489565000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Perception and Treatment Options for Behavioral and Psychological Symptoms of Dementia (BPSD) in Italy"],"prefix":"10.3389","volume":"13","author":[{"given":"Fabrizia","family":"D'Antonio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Tremolizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Zuffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Pomati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Sindem BPSD Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1017\/S1041610297003943","article-title":"Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment","volume":"8","author":"Finkel","year":"1996","journal-title":"Int Psychogeriatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/JGP.0b013e3181d6b68d","article-title":"Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease","volume":"18","author":"Spalletta","year":"2010","journal-title":"Am J Geriatr Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3233\/JAD-2010-101212","article-title":"Grouping and trajectories of the neuropsychiatric symptoms in patients with Alzheimer's disease, Part I: symptom clusters","volume":"22","author":"Garre-Olmo","year":"2010","journal-title":"J Alzheimer's Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1017\/S1041610210001304","article-title":"Neuropsychiatric symptoms and syndromes in institutionalized elderly people without dementia","volume":"23","author":"Cravello","year":"2011","journal-title":"Int Psychogeriatr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00415-013-6893-3","article-title":"Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study","volume":"260","author":"Canevelli","year":"2013","journal-title":"J Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"B7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jalz.2015.05.017","article-title":"Neuropsychiatric symptoms as early manifestations of emergent dementia : provisional diagnostic criteria for mild behavioral impairment","volume":"12","author":"Ismail","year":"2016"},{"key":"B9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/JAD-2010-101836","article-title":"Predicting disease progression in alzheimer's disease: the role of neuropsychiatric syndromes on functional and cognitive decline","volume":"24","author":"Palmer","year":"2011","journal-title":"J Alzheimer's Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/gps.1594","article-title":"The contribution of neuropsychiatric symptoms to the cost of dementia care","volume":"21","author":"Herrmann","year":"2006","journal-title":"Int J Geriatr Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11920-013-0367-2","article-title":"Caregiver health: health of caregivers of Alzheimer's and other dementia patients","volume":"15","author":"Richardson","year":"2013","journal-title":"Curr Psychiatry Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11920-019-1058-4","article-title":"Advances in management of neuropsychiatric syndromes in neurodegenerative diseases","volume":"21","author":"Cummings","year":"2019","journal-title":"Curr Psychiatry Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.14283\/jfa.2020.36","article-title":"Ongoing research protocols for the pharmacological treatment of neuropsychiatric symptoms in dementia","volume":"10","author":"Canevelli","year":"2021","journal-title":"J Frailty Aging."},{"key":"B14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1586\/14737175.3.1.99","article-title":"Provisional diagnostic criteria for depression of Alzheimer's disease: description and review","volume":"3","author":"Olin","year":"2003","journal-title":"Expert Rev Neurother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3233\/JAD-190828","article-title":"Revisiting criteria for psychosis in Alzheimer's Disease and related dementias: toward better phenotypic classification and biomarker research","volume":"73","author":"Fischer","year":"2020","journal-title":"J Alzheimers Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1017\/S1041610214001963","article-title":"Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition","volume":"27","author":"Cummings","year":"2015","journal-title":"Int Psychogeriatr."},{"key":"B17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.eurpsy.2008.09.001","article-title":"Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders","volume":"24","author":"Robert","year":"2009","journal-title":"Eur Psychiatry."},{"key":"B18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.arr.2011.07.002","article-title":"Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms","volume":"11","author":"Azermai","year":"2012","journal-title":"Ageing Res Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jamda.2019.08.027","article-title":"Optimizing Practices, Use, Care and Services-Antipsychotics (OPUS-AP) in Long-term Care Centers in Qu\u00e9bec, Canada: a strategy for best practices","volume":"21","author":"Cossette","year":"2020","journal-title":"J Am Med Dir Assoc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jamda.2018.07.004","article-title":"Exploring antipsychotic prescribing behaviors for nursing home residents with dementia: a qualitative study","volume":"19","author":"Walsh","year":"2018","journal-title":"J Am Med Dir Assoc."},{"key":"B21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1017\/S1041610217001879","article-title":"Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer's disease","volume":"30","author":"Siafarikas","year":"2018","journal-title":"Int Psychogeriatr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s11065-020-09437-5","article-title":"Behavioral and psychological symptoms that predict cognitive decline or impairment in cognitively normal middle-aged or older adults: a meta-analysis","volume":"30","author":"Hudon","year":"2020","journal-title":"Neuropsychol Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"6319826","DOI":"10.1155\/2021\/6319826","article-title":"Revisiting Apathy in Alzheimer's disease: from conceptualization to therapeutic approaches","volume":"2021","author":"Teixeira","year":"2021","journal-title":"Behav Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jad.2017.05.048","article-title":"Emotional blunting with antidepressant treatments: a survey among depressed patients","volume":"221","author":"Goodwin","year":"2017","journal-title":"J Affect Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"109926","DOI":"10.1016\/j.pnpbp.2020.109926","article-title":"From apathy to addiction: Insights from neurology and psychiatry","volume":"101","author":"Kirschner","year":"2020","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cns.12484","article-title":"Role of Donepezil in the management of neuropsychiatric symptoms in Alzheimer's Disease and Dementia with lewy bodies","volume":"22","author":"Cummings","year":"2016","journal-title":"CNS Neurosci Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0167-4943(01)00187-X","article-title":"Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial","volume":"33","author":"Barak","year":"2001","journal-title":"Arch Gerontol Geriatr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/gps.2200","article-title":"Expert opinion on the management of behavioural and psychological symptoms of dementia (BPSD) and investigation into prescribing practices in the UK","volume":"24","author":"Bishara","year":"2009","journal-title":"Int J Geriatr Psychiatry."},{"key":"B29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.30773\/pi.2020.0329","article-title":"The behavioral effects of combination therapy of Memantine and Acetylcholinesterase inhibitors compared with Acetylcholinesterase inhibitors alone in patients with moderate Alzheimer's Dementia: a double-blind randomized placebo-controlled trial","volume":"18","author":"Youn","year":"2021","journal-title":"Psychiatry Investig."},{"key":"B30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/WNN.0000000000000285","article-title":"Impact of Donepezil and Memantine on behavioral and psychological symptoms of Alzheimer Disease: six-month open-label study","volume":"34","author":"Bago Ro\u017dankovi\u0107","year":"2021","journal-title":"Cogn Behav Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mam.2015.05.005","article-title":"Neuropsychiatric symptoms in Alzheimer's disease: what might be associated brain circuits?","author":"Rosenberg","year":"2015","journal-title":"Mol Aspects Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pscychresns.2012.01.008","article-title":"Neuroimaging of delusions in Alzheimer's disease","volume":"202","author":"Ismail","year":"2012","journal-title":"Psychiatry Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jagp.2018.09.016","article-title":"Gray matter changes associated with the development of delusions in Alzheimer Disease","volume":"27","author":"Qian","year":"2019","journal-title":"Am J Geriatr Psychiatry."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/gps.5183","article-title":"Psychosis of Alzheimer's disease: neuropsychological and neuroimaging longitudinal study","volume":"34","author":"D'Antonio","year":"2019","journal-title":"Int J Geriatr Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13825585.2021.1958139","article-title":"Cortical complexity alterations in the medial temporal lobe are associated with Alzheimer's disease psychosis","author":"D'Antonio","year":"2021","journal-title":"Neuropsychol Dev Cogn B Aging Neuropsychol Cogn."},{"key":"B36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000363500","article-title":"Agitation in dementia: relation to core cerebrospinal fluid biomarker levels","volume":"4","author":"Bloniecki","year":"2014","journal-title":"Dement Geriatr Cogn Dis Extra."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.neurobiolaging.2014.03.003","article-title":"Psychotic Alzheimer's disease is associated with gender-specific tau phosphorylation abnormalities","volume":"35","author":"Koppel","year":"2014","journal-title":"Neurobiol Aging."},{"key":"B38","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3233\/JAD-131166","article-title":"Hyperphosphorylated tau is elevated in Alzheimer's disease with psychosis","volume":"39","author":"Murray","year":"2014","journal-title":"J Alzheimers Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/qhc.12.1.18","volume":"12","year":"2003","journal-title":"Qual Saf Health Care"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.843088\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T16:26:07Z","timestamp":1681489567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.843088\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":39,"alternative-id":["10.3389\/fpsyt.2022.843088"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.843088","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"article-number":"843088"}}